Prestige Consumer Healthcare Inc. (PBH): Price and Financial Metrics

Prestige Consumer Healthcare Inc. (PBH): $69.72

0.32 (+0.46%)

POWR Rating

Component Grades

Momentum

C

Stability

B

Sentiment

Quality

C

Add PBH to Watchlist
Sign Up

Industry: Medical - Services

Industry

C

Ranked

#10 of 69

in industry

PBH Price/Volume Stats

Current price $69.72 52-week high $70.00
Prev. close $69.40 52-week low $55.96
Day low $69.41 Volume 167,600
Day high $70.00 Avg. volume 248,705
50-day MA $62.66 Dividend yield N/A
200-day MA $60.21 Market Cap 3.46B

PBH Stock Price Chart Interactive Chart >

PBH POWR Grades

  • Stability is the dimension where PBH ranks best; there it ranks ahead of 82.61% of US stocks.
  • The strongest trend for PBH is in Growth, which has been heading down over the past 26 weeks.
  • PBH ranks lowest in Momentum; there it ranks in the 6th percentile.

PBH Stock Summary

  • Of note is the ratio of PRESTIGE CONSUMER HEALTHCARE INC's sales and general administrative expense to its total operating expenses; only 18.1% of US stocks have a lower such ratio.
  • Over the past twelve months, PBH has reported earnings growth of -106.09%, putting it ahead of merely 12.56% of US stocks in our set.
  • In terms of volatility of its share price, PBH is more volatile than merely 1.81% of stocks we're observing.
  • Stocks that are quantitatively similar to PBH, based on their financial statements, market capitalization, and price volatility, are CVEO, SSP, CTLT, OUT, and GROM.
  • PBH's SEC filings can be seen here. And to visit PRESTIGE CONSUMER HEALTHCARE INC's official web site, go to www.prestigebrands.com.

PBH Valuation Summary

  • In comparison to the median Healthcare stock, PBH's price/sales ratio is 22.73% higher, now standing at 2.7.
  • PBH's price/sales ratio has moved down 9.7 over the prior 230 months.

Below are key valuation metrics over time for PBH.

Stock Date P/S P/B P/E EV/EBIT
PBH 2023-12-29 2.7 2 -37.1 -212.2
PBH 2023-12-28 2.7 2 -37.5 -213.7
PBH 2023-12-27 2.7 2 -37.5 -213.8
PBH 2023-12-26 2.7 2 -37.5 -213.5
PBH 2023-12-22 2.7 2 -37.6 -214.0
PBH 2023-12-21 2.7 2 -37.4 -213.4

PBH Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at 46.93%.
  • Its 4 year net cashflow from operations growth rate is now at 46.93%.
  • Its 4 year price growth rate is now at -19.9%.
PBH's revenue has moved up $88,875,000 over the prior 52 months.

The table below shows PBH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,108.792 233.855 210.332
2022-09-30 1,107.738 245.21 208.596
2022-06-30 1,094.69 248.864 202.898
2022-03-31 1,086.812 259.922 205.381
2021-12-31 1,057.637 255.883 188.809
2021-09-30 1,021.955 238.813 179.467

PBH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PBH has a Quality Grade of C, ranking ahead of 40.37% of graded US stocks.
  • PBH's asset turnover comes in at 0.283 -- ranking 157th of 682 Pharmaceutical Products stocks.
  • GHSI, KPTI, and CDTX are the stocks whose asset turnover ratios are most correlated with PBH.

The table below shows PBH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.283 0.582 0.167
2021-03-31 0.274 0.580 0.159
2020-12-31 0.276 0.579 0.161
2020-09-30 0.277 0.576 0.159
2020-06-30 0.276 0.575 0.152
2020-03-31 0.277 0.573 0.145

PBH Price Target

For more insight on analysts targets of PBH, see our PBH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $63.50 Average Broker Recommendation 1.58 (Moderate Buy)

Prestige Consumer Healthcare Inc. (PBH) Company Bio


Prestige Brands Holdings markets and distributes brand name over-the-counter health-care and household products throughout the U.S., Canada, Australia, and in certain other international markets. Core brands include Monistat women's health products, Nix lice treatments, Chloraseptic sore throat treatments, Compound W wart treatments, Clear Eyes eye care products, Little Remedies pediatric products, The Doctor's NightGuard dental protector, Efferdent denture care products, Luden's throat drops, Dramamine motion sickness treatments, BC and Goody's headache remedies, Beano gas prevention, Debrox earwax remover, and in Canada, Gaviscon antacid. The company was founded in 1996 and is based in Tarrytown, New York.


PBH Latest News Stream


Event/Time News Detail
Loading, please wait...

PBH Latest Social Stream


Loading social stream, please wait...

View Full PBH Social Stream

Latest PBH News From Around the Web

Below are the latest news stories about PRESTIGE CONSUMER HEALTHCARE INC that investors may wish to consider to help them evaluate PBH as an investment opportunity.

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray Due to the Presence of Benzene

Americaine® 20% Benzocaine Topical Anesthetic Spray Americaine® 20% Benzocaine Topical Anesthetic Spray TARRYTOWN, N.Y., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling one lot of Americaine® 20% Benzocaine Topical Anesthetic Spray to the consumer level. While benzene is not an ingredient in any Americaine® 20% Benzocaine Topical Anesthetic Spray products, a recent review by our manufacturer and their th

Yahoo | December 22, 2023

Healthcare Sector Stocks: Consistent Above-Average Growth And Income

The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records.

TalkMarkets.com | December 18, 2023

Should You Invest in Prestige Consumer Healthcare (PBH)?

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2023 investor letter. A copy of the same can be downloaded here. The third quarter saw losses in the U.S. stock market due to concerns about a government shutdown, autoworker strikes, rising oil prices, and the possibility that interest rates might stay higher for longer. […]

Yahoo | November 29, 2023

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene

TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder TARRYTOWN, N.Y., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from tw

Yahoo | November 24, 2023

Prestige Consumer Healthcare's (NYSE:PBH) investors will be pleased with their respectable 70% return over the last three years

One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...

Yahoo | November 8, 2023

Read More 'PBH' Stories Here

PBH Price Returns

1-mo 10.77%
3-mo 20.10%
6-mo 17.18%
1-year 14.46%
3-year 66.91%
5-year 143.52%
YTD 13.88%
2023 -2.20%
2022 3.22%
2021 73.93%
2020 -13.90%
2019 31.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!